Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with high-grade non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread into the bladder muscle), specifically classified as Ta or T1, without a type called CIS — who have already completed standard treatment, whose cancer has come back (shown by a camera examination of the bladder), and who are scheduled for a surgical procedure to remove bladder tumours without chemotherapy applied inside the bladder during that procedure
- People considered to be at high risk of their bladder cancer coming back
- People who have a general physical fitness level rated as 0, 1, or 2 on a standard medical scale (meaning ranging from fully active to capable of self-care but limited in physical activity) (confirm with trial site)
- People whose blood counts and organ function meet specific minimum levels for red blood cells, white blood cells, platelets, liver function, and kidney function, as determined by laboratory tests (confirm with trial site)
Who may not be able to join:
- People who have a history of a specific type of bladder cancer called carcinoma in situ (CIS), or bladder cancer that has grown into the bladder muscle (MIBC)
- People who are currently taking part in another clinical trial involving an experimental treatment
- People who have had allergic reactions to compounds chemically or biologically similar to the study drug (resiquimod/R848), or to specific ingredients used in the trial treatment called poloxamer 407 or sodium hyaluronate
- People who have a serious or uncontrolled illness, such as an active infection, heart failure, unstable chest pain, irregular heartbeat, or a mental health or social situation that would make it difficult to follow the study requirements — note that urinary tract infections are not automatically disqualifying unless they are severe (confirm with trial site)
- Women who are able to become pregnant, regardless of contraceptive use — this applies to the early phases of this trial only; later phases of the study are expected to include this group (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Seth Lerner, MD, Baylor College of Medicine
Phone: 781-605-8632
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability] Phase 1; Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Phase 1; Recurrence free survival time (Phase 2a)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.